Treatment algorithm in hormone-resistant prostate cancer: Practical guidelines

被引：0
|
作者：
Khochikar, Makarand V. [1 ]
机构：
[1] Siddhi Vinayak Ganapati Canc Hosp, Dept Urooncol, Miraj, India
来源：
INDIAN JOURNAL OF UROLOGY | 2007年 / 23卷 / 01期
关键词：
Cancer-specific chemotherapy; castrate levels; hormone-resistant prostate cancer; psycho-oncology; secondary hormonal therapy; supportive care;
D O I：
10.4103/0970-1591.30271
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Treatment of hormone-resistant prostate cancer can be a challenging situation. The first important step in treating this condition is to assess if one has achieved the castrate level or not. If the castrate levels are not achieved, attempt should be made to achieve so. If the castrate level is achieved, then androgen withdrawals may be of help. Supportive care, care of the clinical problems forms an integral part of the treatment. Cancer-specific chemotherapy is certainly an option in progressive disease.
引用
收藏
页码：67 / 69
页数：3
相关论文
共 50 条
  • [11] Weekly epirubicin in patients with hormone-resistant prostate cancer
    Petrioli, R
    Fiaschi, AL
    Pozzessere, D
    Messinese, S
    Sabatino, M
    Marsili, S
    Correale, P
    Manganelli, A
    Salvestrini, F
    Francini, G
    BRITISH JOURNAL OF CANCER, 2002, 87 (07) : 720 - 725
  • [12] Immunotherapy enhanced by geroprotection: Hormone-resistant prostate cancer
    Lasalvia-Prisco, E. M.
    Dau, C.
    Goldschmidt, P.
    Galmarini, F.
    Vazquez, J.
    Lasalvia-Galante, E. E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [13] Residual androgen depending in hormone-resistant prostate cancer
    Fossa, SD
    ACTA ONCOLOGICA, 1997, 36 (01) : 81 - 82
  • [14] Weekly epirubicin in patients with hormone-resistant prostate cancer
    R Petrioli
    A I Fiaschi
    D Pozzessere
    S Messinese
    M Sabatino
    S Marsili
    P Correale
    A Manganelli
    F Salvestrini
    G Francini
    British Journal of Cancer, 2002, 87 : 720 - 725
  • [15] Value of mitoxantrone in hormone-resistant metastatic prostate cancer.
    Khalaf, A
    Pfister, C
    Hellot, MF
    Dunet, F
    Moussu, J
    Grise, P
    PROGRES EN UROLOGIE, 2002, 12 (01): : 37 - 42
  • [16] Neuroendocrine serum tumour markers in hormone-resistant prostate cancer
    Hvamstad, T
    Jordal, A
    Hekmat, N
    Paus, E
    Fosså, SD
    EUROPEAN UROLOGY, 2003, 44 (02) : 215 - 221
  • [17] Role of DNA methyltransferase 1 in hormone-resistant prostate cancer
    Chen, Miao-Fen
    Chen, Wen-Cheng
    Chang, Yu-Jia
    Wu, Ching-Fang
    Wu, Chun-Te
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2010, 88 (09): : 953 - 962
  • [18] Chemotherapy for hormone-resistant prostate cancer: Where are we today?
    Buchler, Tomas
    Harland, Stephen J.
    INDIAN JOURNAL OF UROLOGY, 2007, 23 (01) : 55 - 60
  • [19] Role of DNA methyltransferase 1 in hormone-resistant prostate cancer
    Miao-Fen Chen
    Wen-Cheng Chen
    Yu-Jia Chang
    Ching-Fang Wu
    Chun-Te Wu
    Journal of Molecular Medicine, 2010, 88 : 953 - 962
  • [20] CYTOTOXIC CHEMOTHERAPY FOR ADVANCED HORMONE-RESISTANT PROSTATE-CANCER
    YAGODA, A
    PETRYLAK, D
    CANCER, 1993, 71 (03) : 1098 - 1109
12345